KR20210136217A - Cosmetics for Skin Cell Regeneration - Google Patents

Abstract

The present invention relates to a cosmetic composition for improving skin which comprises the epidermal growth factor (EGF), the fibroblast growth factor 4 (FGF4), ceramide, and copper peptide as active ingredients. Especially, the present invention relates to a composition capable of obtaining an excellent effect for skin improvement by activating fibroblast and activating genes having skin regeneration and wound healing effects.

Description

Cosmetic composition for skin cell regeneration {Cosmetics for Skin Cell Regeneration}

The present invention relates to a composition for cosmetic or external application for skin for improving skin condition, particularly for skin cell regeneration, and a method for preparing the same.

The skin is an organ that is always in contact with the external environment, and it is common to play a role as a protective barrier to prevent water loss. In order to prevent the drying of skin moisture, it develops into a thin stratum corneum while containing moisture through a differentiation process in the epidermal layer.

The stratum corneum is the outermost layer of the skin that is in direct contact with the external environment, preventing the intrusion of mechanical and chemical harmful ingredients and preventing the loss of internal moisture in an external environment that is drier than the living body. is maintaining

However, despite these functions of the skin, it loses its moisturizing power and becomes dry due to bad weather, strong ultraviolet rays, excessive use of face wash, stress, and natural skin aging.

Aging skin is characterized by a decrease in the thickness of the epidermis and dermis, roughening of the skin surface, enlarged pores, the formation of wrinkles, skin color changes including yellow, bronze, or brown spots, telangiectasia or Characteristics such as "broken vein".

Therefore, in order to prevent such skin aging, a cosmetic composition including a cell regeneration factor has been developed, but the development of a cosmetic composition having an optimal effect is further required.

One object of the present invention is epidermal growth factor (EGF), fibroblast growth factor 4 (FGF4), ceramide (Ceramide) and copper peptide (Copper peptide; GHK-Cu) as active ingredients An object of the present invention is to provide a cosmetic composition for improving skin comprising:

Another object of the present invention is to include epidermal growth factor (EGF), fibroblast growth factor 4 (FGF4), ceramide (Ceramide) and copper peptide (GHK-Cu) as active ingredients. An object of the present invention is to provide a pharmaceutical composition for wound healing or skin regeneration.

Hereinafter, various embodiments described herein are described with reference to the drawings. In the following description, various specific details are set forth, such as specific forms, compositions and processes, and the like, for a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or in conjunction with other known methods and forms. In other instances, well-known processes and manufacturing techniques have not been described in specific detail in order not to unnecessarily obscure the present invention. Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, form, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the invention. Thus, references to "in one embodiment" or "an embodiment" in various places throughout this specification do not necessarily refer to the same embodiment of the invention. Additionally, the particular features, forms, compositions, or properties may be combined in any suitable manner in one or more embodiments.

Unless specifically defined in the present invention, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

In the present invention, collagen is a fibrous protein found in many animals, particularly mammals, and occupies most of all connective tissues in the body, such as skin and cartilage. Collagen is like a rope in which three polypeptide molecules are twisted into a triple helix. In each polypeptide chain, glycine and proline are alternately arranged with each other, and several different amino acids are interpolated in the middle.

In the present invention, the collagen may be collagen 1 to 5. The collagen 1 is about 90% of the dermal layer of the skin, 80% of tendons, ducts (ducts, vessels, blood vessels, etc.), ligatures, organs, about 20% of bones (the main component of bone), the main component of tooth dentin, and human 17 It is encoded by COL1A1 on chromosome 1 and COL1A2 on human chromosome 7. The collagen 5 is present on the cell surface, the main component of hair, and in the placenta and is encoded by COL5A1 genes located on human chromosome 9 and COL5A2 genes located on human chromosome 2.

In the present invention, elastin is a core protein of the extracellular matrix. The elastin has high elasticity and is present in connective tissue so that many tissues of the body can resume shape after stretching or contraction, and is an important bearing tissue in the vertebrate body and is used where mechanical energy needs to be stored. The elastin is encoded by the ELN gene of human chromosome 7.

In the present invention, the homeobox protein is a gene encoding a transcription factor class called a homeobox gene in vertebrates in a cluster named A, B, C and D on four separate chromosomes (HOXA, HOXB, HOXC, HOXD). Expression of the homeobox proteins is regulated during embryonic development.

In the present invention, the HOXA3 gene is present on human chromosome 7, is part of the HOXA cluster, and is expressed in mesenchymal neural crest cells and endoderm cells found in the third pharyngeal sac during normal fetal development. Expression of HOXA3 in these cells affects the proper formation of the thymus, thyroid and parathyroid organs.

In the present invention, the HOXD3 gene is present on human chromosome 2, and as a part of the HOXD cluster, the protein encoded by the HOXD3 gene may play a role in regulating the cell adhesion process.

In the present invention, signal transducer and activator of transcription 3 (Signal transducer and activator of transcription 3; STAT3) is a member of the STAT superfamily and is encoded by the STAT3 gene. Since the STAT3 gene mediates the expression of various genes in response to cell stimuli, it plays an important role in many cellular processes such as cell growth and apoptosis.

In the present invention, keratinocyte growth factor (KGF) is also known as FGF7 and is encoded by the KGF gene of human chromosome 15. The FGF7 is a growth factor present in the epithelialization phase of wound healing.

In the present invention, Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) is a technology capable of reliably detecting and measuring products generated during each PCR cycle. The introduction of oligonucleotide probes designed to hybridize within the target sequence made this qRT-PCR possible.

According to one embodiment of the present invention, epidermal growth factor (EGF), fibroblast growth factor 4 (FGF4), ceramide (Ceramide) and copper peptide (Copper peptide GHK-Cu) are effective It relates to a cosmetic composition for skin improvement comprising as an ingredient.

In the present invention, epidermal growth factor (EGF) binds to the receptor EGFR to promote cell growth, proliferation, and differentiation, and human EGF consists of 53 amino acids (Exp Cell Res., 284(1):2). -13, 2003).

In the composition of the present invention, the concentration of the epidermal growth factor (EGF) may be 100 to 1000 ng/ml, and preferably, the epidermal growth factor (EGF) concentration may be 250 to 750 ng/ml. In the present invention, when the concentration of the epidermal growth factor (EGF) is less than 250 ng/ml, the effect of adding the epidermal growth factor (EGF) may be insignificant. Since it is difficult to expect a synergistic effect, the efficiency may decrease according to the addition.

In the composition of the present invention, fibroblast growth factor 4 (Fibroblast growth factor 4; FGF 4) is a protein encoded by the FGF4 gene located on chromosome 11 in humans, the fibroblast growth factor 4 (FGF4) protein on a mouse The fuselage suggests bone-forming and limb developmental functions in the study. Upregulation of fibroblast growth factor 4 (FGF4) in pluripotent stem cells is also used for intestinal organoid production.

In the composition of the present invention, the concentration of the fibroblast growth factor 4 (FGF4) may be 10 to 500 ng/ml, preferably 50 to 200 ng/ml. In the present invention, when the concentration of FGF4 is less than 50 ng/ml, the effect of adding the fibroblast growth factor 4 (FGF4) may be insignificant, and when the concentration exceeds 200 ng/ml, a further synergistic effect is obtained Since it is difficult to expect, the efficiency may be lowered by the addition.

In the present invention, ceramide (Ceramide) is a lipid (waxy lipid) family, composed of sphingosine and fatty acids. The ceramide is found in high concentration in the cell membrane of eukaryotic cells, because it is a component constituting sphingomyelin, one of the main lipids of the lipid bilayer. Unlike other sphingolipids found in cell membranes, ceramides can participate in a variety of cellular signaling.

In the present invention, the ceramide may be included in an amount of 1 to 500 ppm, preferably 10 to 200 ppm. When the concentration of the ceramide in the present invention is less than 10ppm, the effect of adding the ceramide may not appear, and when the concentration exceeds 200ppm, it may rather inhibit the growth of skin cells.

In the present invention, copper peptide (Copper peptide GHK-Cu) is a material in which a peptide is bound to a copper ion, specifically, a form in which a copper ion is bound to the C-terminus of a peptide composed of three amino acids: glycine-histidine-lysine of the copper peptide. A peptide consisting of three amino acids, glycine-histidine-lysine, was first discovered in human serum and also found in saliva and urine. The copper peptide naturally exists in human serum at 200 ng/ml at the age of 20, and then drops to 80 ng/ml at the age of 60.

In the present invention, the copper peptide may be included in an amount of 1 to 100 ppm, preferably 5 to 40 ppm. In the present invention, when the concentration of the copper peptide is less than 5 ppm, the effect of adding the copper peptide may not appear, and when the concentration exceeds 40 ppm, it may rather inhibit the growth of skin cells.

The cosmetic composition of the present invention may further include at least one selected from the group consisting of Schizophyllan (Schizofiran), a placenta extract, panthenol, and a placenta-like growth factor complex (PmGF-X).

The type of solvent that can be further added to the cosmetic composition of the present invention is not particularly limited, but for example, water, saline, DMSO, or a combination thereof may be used, and as a carrier, excipient or diluent, purified water, oil, wax , fatty acids, fatty alcohols, fatty acid esters, surfactants, humectants, thickeners, antioxidants, viscosity stabilizers, chelating agents, buffers, lower alcohols, and the like. In addition, if necessary, it may include a whitening agent, a moisturizer, a vitamin, a sunscreen, a perfume, a dye, an antibiotic, an antibacterial agent, an antifungal agent.

Hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm oil, jojoba oil, and avocado oil may be used as the oil, and beeswax, spermaceti, carnauba, candelilla, montan, ceresin, liquid paraffin, and lanolin may be used as the oil. can be used

As the fatty acid, stearic acid, linoleic acid, linolenic acid, and oleic acid may be used, and as the fatty acid alcohol, cetyl alcohol, octyl dodecanol, oleyl alcohol, panthenol, lanolin alcohol, stearyl alcohol, and hexadecanol may be used. As the fatty acid ester, isopropyl myristate, isopropyl palmitate, and butyl stearate may be used. As the surfactant, cationic surfactants, anionic surfactants and nonionic surfactants known in the art can be used, and surfactants derived from natural products are preferred as far as possible.

In addition, it may include a desiccant, a thickener, an antioxidant, etc. widely known in the cosmetic field, and the types and amounts thereof are as known in the art.

In the present invention, Schiziphyllan (Schizofiran) is also referred to as a trade name MC glucan, and is a polysaccharide having a molecular weight of 10,000 to 80,000 obtained from a culture medium of Schizophyrum commune Fr. As a colorless and tasteless powder, it does not dissolve well in water, but it dissolves slowly and becomes a liquid with high viscosity. Its basic structure is that one molecule of glucose is branched by β-1,6-glucopyranoside bonds to three straight-chain glucose residues that form β-1,3-glucopyranoside bonds. The schizophyllan is known to play a role in stimulating the immune system, transporting metals in aqueous solution, etc. (Kony, David B.; Damm, Wolfgang; Stoll, Serge; Van Gunsteren, Wilfred F.; Hunenberger, Philippe H. (2007)). "Explicit-Solvent Molecular Dynamics Simulations of the Polysaccharide Schizophyllan in Water". Biophysical Journal. 93 (2): 442-55.).

In the present invention, the schizophyllan may be included in an amount of 0.1 to 5% by weight, preferably 0.5 to 2% by weight. In the present invention, when the concentration of schizophyllan is less than 0.5% by weight, the effect of adding sizophyllan may not appear, and when the concentration exceeds 2% by weight, growth of skin cells may be inhibited.

In the present invention, the phytoplacenta may be a portion where the ovary runs in the ovary (ovary). In the present invention, the placenta extract may be a soybean-derived placenta extract. Alternatively, in the present invention, the locust extract may be a rose-derived locust extract. Also, in the present invention, the placenta extract may be a vegetable placenta C (Plant placenta C, Vegetable placenta C), but is not limited thereto.

In the present invention, "extract" is a liquid component obtained by immersing a target substance in a solvent and then extracting it for a certain period of time at room temperature, low temperature, or heating condition, obtained by removing the solvent from the liquid component It means the result of solid content, etc. In addition, in addition to the result, it can be comprehensively interpreted as including all of the diluent of the result, the concentrate thereof, the prepared product thereof, the purified product, and the like.

The method for obtaining the extract of the present invention is not particularly limited, and various extraction methods commonly used in the technical field to which the present invention pertains may be used. For example, the solvents of purified water, methanol, ethanol, glycerin, ethyl acetate, butylene glycol, propylene glycol, dichloromethane, and hexane can be used alone or a mixture of two or more thereof can be used as the extraction solvent. have.

In addition, the extract of the present invention includes an extract extracted by other methods as well as the extract by the above-described extraction solvent. For example, extraction by ultra-high pressure extraction method; extraction by ultrasonic extraction; separation using an ultrafiltration membrane with a constant molecular weight cut-off value; Fractions obtained through various additional purification methods, such as separation by chromatography prepared for separation according to size, charge, hydrophobicity or affinity, etc., are also included in the extract.

In the present invention, the placenta extract may be included in an amount of 0.1 to 5% by weight, preferably 0.5 to 2% by weight. In the present invention, when the concentration of the locust extract is less than 0.5% by weight, the effect of adding the locust extract may not appear, and when the concentration exceeds 2% by weight, the growth of skin cells may be inhibited.

In the present invention, the panthenol (panthenol) is _{an alcohol derivative of pantothenic acid (vitamin B 5} ), which corresponds to a vitamin precursor, and is rapidly oxidized to pantothenic acid in vivo.

In the present invention, the panthenol may be included in an amount of 0.1 to 5% by weight, preferably 0.5 to 2% by weight. In the present invention, when the concentration of the panthenol is less than 0.5% by weight, the effect of adding the panthenol may not appear, and when the concentration exceeds 2% by weight, the growth of skin cells may be inhibited.

In the present invention, placenta mimetic growth factor complex (PmGF-X) is placental growth factor (PGF), stem cell growth factor (SGF), transforming growth factor (Trans) It is a mixture of -forming growth factor beta 1; TGF-β1). The placenta-like growth factor complex (PmGF-X) may be a mixture of the placental growth factor (PGF), the stem cell growth factor (SGF), and the transforming growth factor (TGF-β1) in a 1:1:1 ratio. have.

In the present invention, the placental growth factor (PGF) is a protein encoded by the PGF gene in humans, a sub-member of the vascular endothelial growth factor (VEGF) family, and is responsible for angiogenesis and angiogenesis during embryonic development. is the main molecule. In addition, the placental growth factor is expressed at a low level in organs such as the heart, lung, thyroid gland and skeletal muscle under normal physiological conditions.

In the present invention, the placental growth factor (PGF) may be included in an amount of 0.001 to 0.05 ppm, preferably 0.005 to 0.04 ppm. In the present invention, when the concentration of the placental growth factor (PGF) is less than 0.005 ppm, the effect of adding the placental growth factor (PGF) may not appear, and when the concentration exceeds 0.04 ppm, it may inhibit the growth of skin cells. can

In the present invention, the stem cell growth factor (SGF) is a protein encoded by the SGF gene of chromosome 12, and plays an important role in hematopoietic function during embryonic development. The stem cell growth factor is expressed in hematopoietic organs such as the fetal liver or bone marrow. During development, stem cell growth factors regulate pigmentation by producing melanocytes and melanin pigment. Fetal hematopoietic stem cells are more sensitive to stem cell growth factors than adult hematopoietic stem cells.

In the present invention, the stem cell growth factor (SGF) may be included in an amount of 0.001 to 0.05 ppm, preferably 0.005 to 0.04 ppm. In the present invention, when the concentration of the stem cell growth factor (SGF) is less than 0.005 ppm, the effect of adding the stem cell growth factor (SGF) may not appear, and when the concentration exceeds 0.04 ppm, the growth of skin cells is rather inhibited. can hinder

In the present invention, the transforming growth factor (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines, and is encoded by the human chromosome 19 TGFB1 gene. The transforming growth factor plays an important role in controlling the immune system (Letterio JJ, Roberts AB (1998). "Regulation of immune responses by TGF-beta". Annu. Rev. Immunol. 16: 137-61.).

In the present invention, the transforming growth factor (TGF-β1) may be included in an amount of 0.001 to 0.05 ppm, preferably 0.005 to 0.04 ppm. In the present invention, when the concentration of the transforming growth factor (TGF-β1) is less than 0.005 ppm, the effect of adding the transforming growth factor (TGF-β1) may not appear, and when the concentration exceeds 0.04 ppm, the skin May inhibit cell growth.

The composition of the present invention contains epidermal growth factor (EGF), fibroblast growth factor 4 (FGF4), ceramide and copper peptide (Copper peptide GHK-Cu) as essential components, and optionally, schizophyllan, placenta extract, panthenol and By further including one or more selected from the group consisting of placental-like growth factor complex (PmGF-X), a remarkably excellent skin improvement effect can be imparted.

As used herein, the term "skin improvement" refers to a process of treating, alleviating, or alleviating skin damage caused by intrinsic or extrinsic factors of the skin, or its effects, and more specifically, skin whitening. , wrinkle improvement, elasticity enhancement, skin regeneration, skin moisturizing, anti-aging, skin irritation alleviation, acne prevention or improvement, and/or atopic prevention or improvement effect, preferably skin aging or skin regeneration However, the present invention is not limited thereto.

In the present invention, the cosmetic composition includes lotion, nutritional lotion, nutritional essence, massage cream, cosmetic bath water additive, body lotion, body milk, bath oil, baby oil, baby powder, shower gel, shower cream, sunscreen lotion, sunscreen cream, Suntan cream, skin lotion, skin cream, sunscreen cosmetics, cleansing milk, depilatory {cosmetic}, face and body lotion, face and body cream, skin whitening cream, hand lotion, hair lotion, cosmetic cream, jasmine oil, Bath soap, water soap, beauty soap, shampoo, hand sanitizer (hand cleaner), medicinal soap (for non-medical use), cream soap, facial wash, whole body cleaner, scalp cleaner, hair conditioner, makeup soap, tooth whitening gel, toothpaste, etc. form can be prepared. To this end, the composition of the present invention may further include a solvent or a suitable carrier, excipient or diluent commonly used in the preparation of cosmetic compositions.

According to another embodiment of the present invention, including epidermal growth factor (EGF), fibroblast growth factor 4 (FGF4), ceramide and copper peptide as active ingredients, wound healing or skin regeneration It relates to a pharmaceutical composition for use.

In the present invention, the epidermal growth factor (EGF) concentration is 100 to 1000 ng/ml, preferably, the epidermal growth factor (EGF) concentration is 250 to 750 ng/ml. In the present invention, when the concentration of the epidermal growth factor (EGF) is out of the range of 250 to 750 ng/ml, the effect of adding the epidermal growth factor (EGF) may be insignificant or the efficiency according to the addition may be reduced.

In the present invention, the fibroblast growth factor 4 (FGF4) concentration is 10 to 500 ng/ml, preferably 50 to 200 ng/ml. In the present invention, when the concentration of the fibroblast growth factor 4 (FGF4) is out of the range of 50 to 200 ng/ml, the effect of adding the fibroblast growth factor 4 (FGF4) may be insignificant or the efficiency may be reduced. .

In the present invention, the ceramide may be included in an amount of 1 to 500 ppm, preferably 10 to 200 ppm. When the concentration of the ceramide in the present invention is less than 10ppm, the effect of adding the ceramide may not appear, and when the concentration exceeds 200ppm, it may rather inhibit the growth of skin cells.

In the present invention, the copper peptide may be included in an amount of 1 to 100 ppm, preferably 5 to 40 ppm. In the present invention, when the concentration of the copper peptide is less than 5 ppm, the effect of adding the copper peptide may not appear, and when the concentration exceeds 40 ppm, it may rather inhibit the growth of skin cells.

In the present invention, the pharmaceutical composition may further include one or more selected from the group consisting of schizophyllan, placenta extract, panthenol, and placental-like growth factor complex.

In the present invention, the schizophyllan may be included in an amount of 0.1 to 5% by weight, preferably 0.5 to 2% by weight. In the present invention, when the concentration of schizophyllan is less than 0.5% by weight, the effect of adding sizophyllan may not appear, and when the concentration exceeds 2% by weight, growth of skin cells may be inhibited.

In the present invention, the placenta extract may be included in an amount of 0.1 to 5% by weight, preferably 0.5 to 2% by weight. In the present invention, when the concentration of the locust extract is less than 0.5% by weight, the effect of adding the locust extract may not appear, and when the concentration exceeds 2% by weight, the growth of skin cells may be inhibited.

In the present invention, the panthenol may be included in an amount of 0.1 to 5% by weight, preferably 0.5 to 2% by weight. In the present invention, when the concentration of the panthenol is less than 0.5% by weight, the effect of adding the panthenol may not appear, and when the concentration exceeds 2% by weight, the growth of skin cells may be inhibited.

In the present invention, the placental growth factor (PGF) may be included in an amount of 0.001 to 0.05 ppm, preferably 0.005 to 0.04 ppm. In the present invention, when the concentration of the placental growth factor (PGF) is less than 0.005 ppm, the effect of adding the placental growth factor (PGF) may not appear, and when the concentration exceeds 0.04 ppm, it may inhibit the growth of skin cells. can

In the present invention, the stem cell growth factor (SGF) may be included in an amount of 0.001 to 0.05 ppm, preferably 0.005 to 0.04 ppm. In the present invention, when the concentration of the stem cell growth factor (SGF) is less than 0.005 ppm, the effect of adding the stem cell growth factor (SGF) may not appear, and when the concentration exceeds 0.04 ppm, the growth of skin cells is rather inhibited. can hinder

In the present invention, the transforming growth factor (TGF-β1) may be included in an amount of 0.001 to 0.05 ppm, preferably 0.005 to 0.04 ppm. In the present invention, when the concentration of the transforming growth factor (TGF-β1) is less than 0.005 ppm, the effect of adding the transforming growth factor (TGF-β1) may not appear, and when the concentration exceeds 0.04 ppm, the skin May inhibit cell growth.

In the present invention, the description of the epidermal growth factor (EGF), Kupffer peptide, fibroblast growth factor 4 (FGF4), ceramide, schizophyllan, placenta extract, panthenol, and placenta-like growth factor overlaps with those described above and excessive complexity of the specification In order to avoid this, detailed description thereof will be omitted below.

In the present invention, the pharmaceutical composition may be characterized in the form of capsules, tablets, granules, injections, ointments, powders or beverages, and the pharmaceutical composition may be characterized in that it is for humans or animals.

In the present invention, "healing" may include without limitation any action in which symptoms of various diseases are improved or beneficial by using the composition of the present invention.

The pharmaceutical composition of the present invention is not limited thereto, but each can be formulated in the form of oral dosage forms such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injection solutions according to conventional methods. can The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, dyes, fragrances, etc., for oral administration, and in the case of injections, buffers, preservatives, pain-freezing agents A topical agent, solubilizer, isotonic agent, stabilizer, etc. may be mixed and used, and in the case of topical administration, a base, excipient, lubricant, preservative, etc. may be used. The dosage form of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above. For example, in the case of oral administration, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be prepared in the form of unit dose ampoules or multiple doses. have. In addition, it can be formulated as a solution, suspension, tablet, capsule, sustained release formulation, and the like.

The composition for external application for skin of the present invention can provide a skin barrier protection effect on skin damaged by burns or cuts, dry skin, or sensitive skin through the skin improvement effect.

The external preparation for skin of the present invention may be applied to the human body in various ways or forms by applying the composition of the present invention, but preferably may be prepared in the form of an external preparation for skin applicable by being topically applied to the skin. For example, powders, solutions, suspensions, emulsions, gels, drops, suppositories, creams, ointments, patches, pads or sprays may be mentioned, but are not limited thereto.

In the present invention, when formulated with the composition for external application for skin, in addition to the composition of the present invention, as additives, for example, excipients, wettable powders, emulsification accelerators, suspending agents, salts or buffers for osmotic pressure control, colorants, spices, stabilizers, preservatives, It can be prepared by appropriately mixing preservatives or other compatible adjuvants. The additives are commonly used in the art, and can be formulated within a range that does not impair the purpose and effect of the present invention.

The composition provided in the present invention activates skin fibroblasts, increases mobility, and activates genes related to skin regeneration and wound healing, and thus has a very excellent effect on skin improvement.

1 is a photograph showing changes in cell mobility after treatment of the composition of Comparative Example 1 on skin fibroblasts.
Figure 2 shows the measurement of mobility by treating the composition of Comparative Example 2 on skin fibroblasts.
3 shows the measurement of mobility by treating the composition of Preparation Example 1 to skin fibroblasts.
Figure 4 shows the measurement of mobility by treating the composition of Preparation Example 2 to skin fibroblasts.
Figure 5 shows the change in the amount of cells after treating the skin fibroblasts with the compositions of Preparation Example 1 (#3), Preparation Example 2 (#4), Comparative Example 1 (#1), and Non-Example 2 (#2). The measurement results are presented in a graph.
6 shows a graph comparing COL1A1 gene expression levels when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
7 shows a graph comparing COL1A2 gene expression levels when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
8 shows a graph comparing the expression level of COL5A1 gene when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
9 shows a graph comparing COL5A2 gene expression levels when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
Figure 10 shows a graph comparing the ELN gene expression level when the skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
11 shows a graph comparing KGF gene expression levels when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
12 shows a graph comparing HOXA3 gene expression levels when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
13 shows a graph comparing HOXD3 gene expression levels when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
14 shows a graph comparing STAT3 gene expression levels when skin fibroblasts were treated with the compositions of Comparative Example 2 (#2) and Preparation Example 1 (#3).
15 shows a graph comparing COL1A1 gene expression levels when skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
Figure 16 shows a graph comparing the COL1A2 gene expression level when the skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
17 shows a graph comparing COL5A1 gene expression levels when skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
18 shows a graph comparing COL5A2 gene expression levels when skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
19 shows a graph comparing the ELN gene expression level when the skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
Figure 20 shows a graph comparing the KGF gene expression level when the skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
21 shows a graph comparing HOXA3 gene expression levels when skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
22 shows a graph comparing HOXD3 gene expression levels when skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
23 shows a graph comparing the STAT3 gene expression level when the skin fibroblasts were treated with the compositions of Preparation Examples 1 (#3) and 2 (#4).
24 shows the results of treatment with the composition of Comparative Example 3 on skin fibroblasts.
25 shows the results of treatment with the composition of Comparative Example 4 on skin fibroblasts.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .

[Preparation Examples 1 and 2] Preparation of cosmetic compositions

With the composition shown in Table 1 below, EGF, FGF4, schizophyllan (MC glucan), ceramide, plant placenta C, panthenol, copper peptide, placenta growth factor (PGF), stem cell growth factor (Stem cell factor) ; SGF) or transforming growth factor (Transforming growth factor beta 1; TGF-β1) was prepared by combining the compositions of Preparation Examples 1 and 2. The remainder is a solvent containing purified water, 1,2-hexanediol, ethylhexylglycerin, polysorbate 20, lecithin, and butylene glycol.

ingredient Preparation Example 1 Preparation 2 EGF 500 ng/ml 500 ng/ml FGF4 100 ng/ml 100 ng/ml Sizophyllan (MC Glucan) - 1% by weight Ceramide Soluble Liquid 50ppm 50ppm Phylderm Vegetal C - 0.68% by weight panthenol - 0.75% by weight Cooper Peptide 10ppm 10ppm Placental Growth Factor (PGF) - 0.01ppm Stem cell growth factor (SGF) - 0.01ppm Transforming growth factor (TGF-β1) - 0.01ppm menstruum balance balance

[Comparative Examples 1 and 2] Preparation of cosmetic compositions

The compositions of Comparative Examples 1 and 2 were prepared by combining EGF, FGF4, ceramide, and copper peptide in the composition shown in Table 2 below to compare the composition prepared in Preparation Examples 1 and 2 and the skin regeneration effect below.

ingredient Comparative Example 1 Comparative Example 2 EGF 500 ng/ml 500 ng/ml FGF4 100 ng/ml - Sizophyllan (MC Glucan) - - Ceramide Soluble Liquid - 50ppm Phylderm Vegetal C - - panthenol - - Cooper Peptide 10ppm 10ppm Placental Growth Factor (PGF) - - Stem cell growth factor (SGF) - - Transforming growth factor (TGF-β1) - - menstruum balance balance

[Comparative Examples 3 and 4] Preparation of cosmetic compositions

In order to compare the skin regeneration effects with the compositions prepared in Preparation Examples 1 and 2 below, the compositions of Comparative Examples 3 and 4 were prepared with the compositions shown in Table 3 below.

ingredient Comparative Example 3 Comparative Example 4 EGF 500 ng/ml 500 ng/ml FGF4 100 ng/ml 100 ng/ml Sizophyllan (MC Glucan) 5% by weight 10% by weight Ceramide Soluble Liquid 250ppm 500ppm Phylderm Vegetal C 3.4% by weight 6.8% by weight panthenol 3.75% by weight 7.5% by weight Cooper Peptide 50ppm 100ppm Placental Growth Factor (PGF) 0.05ppm 0.1ppm Stem cell growth factor (SGF) 0.05ppm 0.1ppm Transforming growth factor (TGF-β1) 0.05ppm 0.1ppm menstruum balance balance

[Experimental Example 1] Mobility evaluation of skin fibroblasts

Cell migration ability was evaluated by treating skin fibroblasts with the compositions prepared in Preparation Examples 1 and 2, and the results are shown in FIGS. 3 and 4, respectively. In addition, skin fibroblasts were treated with the compositions prepared in Comparative Examples 1 and 2 to evaluate cell migration ability, and the results are shown in FIGS. 1 and 2 , respectively.

The dotted line in FIGS. 1 to 4 is before the fibroblasts move, the upper photos of each of FIGS. 1 to 4 are taken before the skin fibroblasts are treated with a culture solution and the lower photos are on the skin fibroblasts. The picture was taken after 24 hours had elapsed after the composition was treated.

1 to 4, when the skin fibroblasts were treated with the composition of Preparation Examples 1 (#3) to 2 (#4), the composition of Comparative Examples 1 (#1) to 2 (#2) was treated Unlike one case, the movement of skin fibroblasts was observed, and in particular, when the composition of Preparation Example 2 was treated, the movement of skin fibroblasts was the most active.

[Experimental Example 2] Evaluation of cell proliferation rate of skin fibroblasts

When skin fibroblasts were treated with the compositions of Preparation Examples 1 and 2 and Comparative Examples 1 and 2, the change in the amount of cells was measured. After seeding 60,000 cells in each of the first cells in a 24-well cell culture plate, the number of cells was measured 24 hours later, and the cell proliferation rate is shown as a graph in FIG. 5 .

As a result, as shown in FIG. 5, when the compositions of Comparative Example 1 (#1) and Comparative Example 2 (#2) were treated, the number of skin fibroblasts increased to approximately 71,000 or 64,000, but Preparation Example 1 (# 3) and when the composition of Preparation Example 2 (#4) was treated, the number of skin fibroblasts was significantly increased to approximately 78,000 or 77,000. That is, it was found that the compositions of Preparation Examples 1 and 2 were excellent in the ability to improve the proliferation rate of skin fibroblasts compared to the compositions of Comparative Examples 1 and 2.

[Experimental Example 3] Cell activation gene expression evaluation

After treating skin fibroblasts with the compositions to confirm the skin regeneration and wound healing efficacy of the compositions of Preparation Examples 1 (#3) to 2 (#4), qRT-PCR of genes related to skin regeneration and wound healing The expression level was measured and the results are shown in FIGS. 6 to 23 . Here, the collagen genes related to skin regeneration are COL1A1 and COL1A2 genes, the collagen genes related to the scalp are COL5A1 and COL5A2 genes, and elastin and keratinocyte growth factor related genes are ELN and KGF genes. Genes encoding electronic factors regulating re-epithelialization activity in HOXA3, HOXD3 and STAT3 genes.

As shown in FIGS. 6 to 14 , COL1A1, COL1A2, COL5A1, COL5A2, ELN when the skin fibroblasts were treated with the composition of Preparation Example 1 (#3) than when the composition of Comparative Example 2 (#2) was treated. , it was confirmed that the expression of KGF, HOXA3, HOXD3 and STAT3 genes was significantly increased.

In addition, as in FIGS. 15 to 23, when the skin fibroblasts were treated with the composition of Preparation Example 2 (#4), the expression of COL1A1, COL1A2, COL5A1, COL5A2, ELN, KGF, HOXA3, HOXD3 and STAT3 genes was A further increase could be observed.

[Experimental Example 4] Evaluation of activation of skin fibroblasts according to concentration

After 24 hours had elapsed after the skin fibroblasts were treated with the compositions of Comparative Examples 3 and 4, the state of the skin fibroblasts was observed, and the results are shown in FIGS. 24 and 25 .

24 and 25, when the compositions of Comparative Examples 3 and 4 were treated, it was confirmed that the skin fibroblasts did not proliferate, but rather all died.

Although the embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and variations are possible within the scope without departing from the technical spirit of the present invention described in the claims. It will be apparent to those of ordinary skill in the art.

Claims (25)

Epidermal growth factor (EGF), fibroblast growth factor 4 (Fibroblast growth factor 4; FGF4), comprising a ceramide and copper peptide as active ingredients, a cosmetic composition for skin improvement. According to claim 1,
The concentration of the epidermal growth factor is 100 to 1000 ng / ml, a cosmetic composition for skin improvement. According to claim 1,
The concentration of the fibroblast growth factor 4 is 10 to 500 ng / ml, a cosmetic composition for skin improvement. According to claim 1,
The ceramide is contained in an amount of 1 to 500 ppm, a cosmetic composition for skin improvement. According to claim 1,
The cooper peptide is contained in an amount of 1 to 100 ppm, a cosmetic composition for skin improvement. According to claim 1,
The cosmetic composition includes schizophyllan, placenta extract, panthenol, placental growth factor (PGF), stem cell growth factor (SGF) and transforming growth factor beta 1; TGF -β1) A cosmetic composition for improving skin, further comprising at least one selected from the group consisting of. 7. The method of claim 6,
The sizophyllan is contained in an amount of 0.1 to 5% by weight, a cosmetic composition for skin improvement. 7. The method of claim 6,
The constellation extract is contained in an amount of 0.1 to 5% by weight, a cosmetic composition for skin improvement. 7. The method of claim 6,
The panthenol is contained in an amount of 0.1 to 5% by weight, a cosmetic composition for skin improvement. 7. The method of claim 6,
The placental growth factor (PGF) is contained in an amount of 0.001 to 0.05 ppm, a cosmetic composition for skin improvement. 7. The method of claim 6,
The stem cell growth factor (SGF) is contained in an amount of 0.001 to 0.05 ppm, a cosmetic composition for skin improvement. 7. The method of claim 6,
The transforming growth factor (TGF-β1) is contained in an amount of 0.001 to 0.05 ppm, a cosmetic composition for skin improvement. According to claim 1,
The skin improvement is for skin aging prevention or skin regeneration, cosmetic composition. Epidermal growth factor (EGF), fibroblast growth factor 4 (Fibroblast growth factor 4; FGF4), comprising a ceramide and copper peptide as active ingredients, a pharmaceutical composition for wound healing or skin regeneration. 15. The method of claim 14,
The concentration of the epidermal growth factor is 100 to 1000 ng/ml, a pharmaceutical composition for wound healing or skin regeneration. 15. The method of claim 14,
The concentration of the fibroblast growth factor 4 is 10 to 500 ng / ml, a pharmaceutical composition for wound healing or skin regeneration. 15. The method of claim 14,
The ceramide is contained in an amount of 1 to 500 ppm, a pharmaceutical composition for wound healing or skin regeneration. 15. The method of claim 14,
The copper peptide is contained in an amount of 1 to 100 ppm, a pharmaceutical composition for wound healing or skin regeneration. 15. The method of claim 14,
The pharmaceutical composition, schizophyllan, placenta extract, panthenol, placental growth factor (PGF), stem cell growth factor (Stem cell factor; SGF) and transforming growth factor (Transforming growth factor beta 1; A pharmaceutical composition for wound healing or skin regeneration, further comprising one or more selected from the group consisting of TGF-β1). 20. The method of claim 19,
The pharmaceutical composition for wound healing or skin regeneration, wherein the sizophyllan is contained in an amount of 0.1 to 5% by weight. 20. The method of claim 19,
The placenta extract is contained in 0.1 to 5% by weight, a pharmaceutical composition for wound healing or skin regeneration. 20. The method of claim 19,
The panthenol is contained in 0.1 to 5% by weight, a pharmaceutical composition for wound healing or skin regeneration. 20. The method of claim 19,
The placental growth factor (PGF) is contained in an amount of 0.001 to 0.05 ppm, a pharmaceutical composition for wound healing or skin regeneration. 20. The method of claim 19,
The stem cell growth factor (SGF) is contained in an amount of 0.001 to 0.05 ppm, a pharmaceutical composition for wound healing or skin regeneration. 20. The method of claim 19,
The transforming growth factor (TGF-β1) is contained in an amount of 0.001 to 0.05 ppm, a pharmaceutical composition for wound healing or skin regeneration.

Images